AlphaYou
Overview
8 funds hold it, insiders have been net selling, and 8 straight earnings beats.
Key stats
Sep 7- Open
- $445.67
- 52-wk high
- $447.03
- High
- $445.82
- 52-wk low
- $262.49
- Low
- $438.08
- Prev close
- $442.84
- Mkt cap
- $236.38B
- P/E
- 27.2x
- Volume
- 1.84M
- Fwd P/E
- 18.2x
- Beta
- 0.43
- Div yield
- 2.21%
- P/S
- 6.2x
- P/B
- 20.5x
- Profit margin
- +23.0%
- Op margin
- +35.5%
- ROE
- +91.5%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsSmart money
8 funds hold a position and insiders have been net selling.
What funds are doing
Activist stakes, short interest & more
Earnings
Earnings came in 12.3% above what analysts expected.
Earnings per share
$5.60 expected
Revenue
No comparable estimate
FY2026 guidance
$38.20B to $39.40B
No comparable estimate
What the street expects next
EPS expected
$5.48 to $6.16
Revenue expected
25 analysts
Last 30 days
Split both ways
Estimate drift
Change in 30 days
What the company said
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $9.56B | $9.90B | $8.62B | $10.05B |
| Cost of what it sold | $3.08B | $1.79B | $2.74B | $2.81B |
| Gross profit | $6.47B | $8.11B | $5.87B | $7.24B |
| What it spent | ||||
| Research and development | $1.90B | $2.15B | $1.72B | $1.87B |
| Sales and admin | $1.72B | $1.95B | $1.60B | $1.75B |
| Other operating costs | $329.0M | $61.0M | -$113.0M | $116.0M |
| Total operating expenses | $3.95B | $4.16B | $3.21B | $3.73B |
| What was left | ||||
| Operating profit | $2.53B | $3.94B | $2.67B | $3.51B |
| Interest on debt | $685.0M | $653.0M | $657.0M | $673.0M |
| Profit before tax | $3.92B | $1.51B | $2.08B | $2.77B |
| Tax | $705.0M | $181.0M | $265.0M | $393.0M |
| Net profit | $3.22B | $1.33B | $1.82B | $2.38B |
| EBITDA | $5.91B | $3.30B | $3.86B | $3.44B |
Technicals
Price structure
This stock is in a strong uptrend, and looks overbought after a fast run-up.
Trend
Strong uptrend
85 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage is bullish
Tone of tracked coverage
Amgen (AMGN) Says Repatha Reduced Mortality Before a First Heart Attack or Stroke. Can Earlier Use Expand the Market?
BullishSep 4Tudor Financial Inc. Sells 5,697 Shares of Amgen Inc. $AMGN
NeutralSep 4NWF Advisory Services Inc. Sells 4,116 Shares of Amgen Inc. $AMGN
NeutralSep 4Wells Fargo Adjusts Price Target on Amgen to $435 From $400, Keeps Equalweight Rating
Leans bullishSep 4Concurrent Investment Advisors LLC Has $18.70 Million Stock Holdings in Amgen Inc. $AMGN
BullishSep 4TScan Therapeutics Cuts 75% of Staff, Pivots to In Vivo TCR-T for Solid Tumors
Leans bearishSep 3Is Johnson & Johnson Stock Priced For More Growth Than It Has Guided?
NeutralSep 3ESC: Amgen CMO flags Repatha 'inflection' amid new data on mortality benefit
BullishSep 3
Macro
32 macro signals shaping AMGN right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results